References
- Yakoub M, Dulac O, Jambaque I, et al. Early diagnosis of severe myoclonic epilepsy in infancy. Brain Dev. 1992;14:299–303.
- Hurst DL. Epidemiology of severe myoclonic epilepsy in infancy. Epilepsia. 1990;31:397–400.
- Dravet C. Les epilepsies graves de l’enfant. Vie Med. 1978;8:5.
- Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68:1327–1332.
- Nabbout R, Gennaro E, Dalla Bernardina B, et al. Spectrum of SCN1A mutations in severe myoclonic epilepsy of infancy. Neurology. 2003;60:1961–1967.
- Marini C, Scheffer IE, Nabbout R, et al. SCN1A duplications and deletions detected in Dravet syndrome: implications for molecular diagnosis. Epilepsia. 2009;50:1670–1678.
- Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52(Suppl. 2):3–9.
- Harkin LA, McMahon JM, Iona X, et al. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain. 2007;130:843–852.
- Specchio N, Balestri M, Trivisano M, et al. Electroencephalographic features in Dravet syndrome: five-year follow-up study in 22 patients. J Child Neurol. 2012;27:439–444.
- Guerrini R, Striano P, Catarino C, et al. Neuroimaging and neuropathology of Dravet syndrome. Epilepsia. 2011;52(Suppl 2):30–34.
- Aras LM, Isla J, Mingorance‐Le Meur A. The European patient with Dravet syndrome: results from a parent‐reported survey on antiepileptic drug use in the European population with Dravet syndrome. Epilepsy Behav. 2015;44:104–109.
- Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009. Epilepsia. 2010;51:676–685.
- Nabbout R, Chemaly N, Chipaux M, et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis. 2013;8:176.
- Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. Pediatr Neurol. 2017;68:18–34.e3.
- Brigo F, Igwe SC, Bragazzi NL. Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsy. Cochrane Database Syst Rev. 2017;5:CD010483.
- Quilichini PP, Chiron C, Ben-Ari Y, et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia. 2006;47:704–716.
- Fisher JL. The anti-convulsantstiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator. Neuropharmacology. 2009;56:190–197.
- Brigo F, Ausserer H, Tezzon F, et al. When one plus one makes three: the quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy. Epilepsy Behav. 2013;27:439–442.
- Brigo F. Pharmacodynamic interaction between stiripentol and benzodiazepines: from molecular to clinical studies. Epilepsy Behav. 2013;29:586.
- Chiron C. Stiripentol. Expert Opin Investig Drugs. 2005;14:905–911.
- Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group. Lancet. 2000;356:1638–1642.
- Guerrini R, Tonnelier S, d’Athis P, et al. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial. Epilepsia. 2002;43:155.
- Brigo F, Igwe SC, Bragazzi NL. Stiripentol add-on therapy for focal refractory epilepsy. Cochrane Database Syst Rev. 2018;5:CD009887.
- Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007;69:250–254.
- Shi XY, Tomonoh Y, Wang WZ, et al. Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes. Brain Dev. 2016;38:40–46.
- Knupp KG, Wirrell EC. Treatment strategies for Dravet syndrome. CNS Drugs. 2018;32:335–350.
- Yan N, Xin-Hua W, Lin-Mei Z, et al. Prospective study of the efficacy of a ketogenic diet in 20 patients with Dravet syndrome. Seizure. 2018;60:144–148.
- Caraballo RH, Cersósimo RO, Sakr D, et al. Ketogenic diet in patients with Dravet syndrome. Epilepsia. 2005 Sep;46(9):1539–1544.
- Veggiotti P, Burlina A, Coppola G, et al. The ketogenic diet for Dravet syndrome and other epileptic encephalopathies: an Italian consensus. Epilepsia. 2011;52(2):83–89.
- Dressler A, Trimmel-Schwahofer P, Reithofer E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015 Jan;109:81–89.
- Zamponi N, Passamonti C, Cappanera S, et al. Clinical course of young patients with Dravet syndrome after vagal nerve stimulation. Eur J Paediatr Neurol. 2011;15(1):8–14.
- Lotte J, Haberlandt E, Neubauer B, et al. Bromide in patients with SCN1A-mutations manifesting as Dravet syndrome. Neuropediatrics. 2012;43(1):17–21.
- Mueller A, Boor R, Coppola G, et al. Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome. Epilepsy Behav. 2011;21:282–284.
- Dalic L, Mullen SA, Roulet Perez E, et al. Lamotrigine can be beneficial in patients with Dravet syndrome. Dev Med Child Neurol. 2015;57(2):200–202.
- Anderson LL, Hawkins NA, Thompson CH, et al. Unexpected efficacy of a novel sodium channel modulator in Dravet syndrome. Sci Rep. 2017;7(1):1682.
- Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011–2020.
- Lagae L, Brambilla I, Mingorance A, et al. Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey. Dev Med Child Neurol. 2018 Jan;60(1):63–72.
- Meisler M, 2016. Gene therapy for Dravet syndrome – When and how? [cited 2018 Nov 5]. Available from: https://www.dravetfoundation.org/dsf-funded-research/gene-therapy-for-dravet-syndrome/
- Griffin A, Hamling KR, Knupp K, et al. Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain. 2017;140:669–683.
- Escayg A, Heils A, MacDonald BT, et al. A novel SCN1A mutation associated with generalized epilepsy with febrile seizures plus–and prevalence of variants in patients with epilepsy. Am J Hum Genet. 2001;68:866–873.
- Sadleir LG, Mountier EI, Gill D, et al. Not all SCN1A epileptic encephalopathies are Dravet syndrome: early profound Thr226Met phenotype. Neurology. 2017;89:1035–1042.
- Ohmori I, Ouchida M, Miki T, et al. A CACNB4 mutation shows that altered Ca(v)2.1 function may be a genetic modifier of severe myoclonic epilepsy in infancy. Neurobiol Dis. 2008;32:349–354.
- Cheah CS, Yu FH, Westenbroek RE, et al. Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. Proc Natl Acad Sci USA. 2012;109:14646–14651.
- Richards KL, Milligan CJ,. Richardson RJ et al. Selective NaV1.1 activation rescues Dravet syndrome mice from seizures and premature death. Proc Natl Acad Sci USA. 2018 Aug 3:201804764. Epub ahead of print. DOI:10.1073/pnas.1804764115.
- Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55:791–802.
- Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29:574–577.
- Devinsky O, Patel AD, Thiele EA, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204–e1211.
- Schoonjans AS, Lagae L, Ceulemans B. Low‐dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome. Ther Adv Neurol Disord. 2015;8:328–338.
- Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA. 2000;283:1703–1709.
- Gentsch K, Heinemann U, Schmitz B, et al. Fenfluramine blocks low-Mg2+-induced epileptiform activity in rat entorhinal cortex. Epilepsia. 2000;41:925–928.
- Sourbron J, Schneider H, Kecskés A, et al. Serotonergic modulation as effective treatment for Dravet syndrome in a zebrafish mutant model. ACS Chem Neurosci. 2016;7(5):588–598.
- Sourbron J, Smolders I, de Witte P, et al. Pharmacological analysis of the anti-epileptic mechanisms of fenfluramine in scn1a mutant zebrafish. Front Pharmacol. 2017;8:191.
- Boel M, Casaer P. Add-on therapy of fenfluramine in intractable self-induced epilepsy. Neuropediatrics. 1996;27:171–173.
- Ceulemans B, Boel M, Leyssens K, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53:1131–1139.
- Schoonjans A, Paelinck BP, Marchau F, et al. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients. Eur J Neurol. 2017;24:309–314.
- ZOGENIX. 2018. [cited 2018 Nov 5]. Available from: https://dravet.de/wp-content/uploads/2018/03/ZX008-_9.29.17.pdf
- Sullivan J, Lagae L, Knupp K, et al. Effect of ZX008 (fenfluramineHCl oral solution) on total seizures in Dravet syndrome in a phase 3 clinical trial. AAN 2018Abstract #P4.467. [cited 2018 Nov 5]. Available from: https://www.aan.com/conferences-community/annual-meeting/abstracts-and-awards/emerging-science/
- GLOBENEWSWIRE.COM. 2018. [cited 2018 Nov 5]. Available from: https://globenewswire.com/news-release/2018/01/31/1329635/0/en/Zogenix-Completes-Enrollment-in-Second-ZX008-Phase-3-Clinical-Trial-in-Dravet-Syndrome.html
- [cited 2018 Nov 5]. Available from: globenewswire.com/news-release/2018/07/12/1536420/0/en/Zogenix-Announces-Positive-Top-line-Results-from-Second-Pivotal-Phase-3-Clinical-Trial-of-ZX008-in-Dravet-Syndrome.html
- Iannetti P, Parisi P, Spalice A, et al. Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res. 2009;85:89–95.
- Nicita F, Spalice A, Raucci U, et al. The possible use of the L-type calcium channel antagonist verapamil in drug-resistant epilepsy. Expert Rev Neurother. 2016;16:9–15.
- Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43:9–18.
- Angehagen M, Margineanu DG, Ben-Menachem E, et al. Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neurons. Neuroreport. 2003;14:471–475.
- Striano P. Comment to: addition of verapamil in the treatment of severe myoclonic epilepsy in infancy (Iannetti et al.). Epilepsy Res. 2009;86:97–98.
- Nicita F, Spalice A, Papetti L, et al. Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study. Seizure. 2014;23:36–40.
- Nabbout R, Auvin S, Chiron C, et al. Development and content validation of a preliminary core set of patient- and caregiver-relevant outcomes for inclusion in a potential composite endpoint for Dravet syndrome. Epilepsy Behav. 2018;78:232–242.
- Villas N, Meskis MA, Goodliffe S. Dravet syndrome: characteristics, comorbidities, and caregiver concerns. Epilepsy Behav. 2017;74:81–86.